Answers are grounded in this paper and cite their sources.
Assesses LCI's effectiveness in detecting treatment response to inhaled tobramycin in children with cystic fibrosis, suggesting its usefulness over FEV1.
Background: Several outcome measures to assess the efficacy of therapeutic interventions in patients with cystic fibrosis (CF) have been used. Objective: To assess the ability of LCI to detect a treatment response to inhaled tobramycin (tobramycin inhaled solution, TIS) in paediatric patients with CF colonized with pseudomonas aeruginosa. Method: Multiple breath washout and spirometry were performed by 15 children and adolescents with mild CF prior and post a four – week course of TIS. Results: Mean age of the study population was 11.7 years, mean baseline FEV 1 was 99.1% predicted (±15), while mean LCI was 10.3 (±3.1). Mean LCI improved significantly after a four-week course of TIS and deteriorated following a four-week off medication (mean change after TIS: -1.38, p:0.015; mean change after washout period: +1.75; p:0.000). Mean FEV 1 did not change significantly after TIS or after discontinuation of treatment (p: 0.638 and p: 0.783, respectively). Conclusions: Lung clearance index, but not FEV 1 was able to detect a treatment effect from TIS inhalation in patients with CF.
No takes yet. Share an insight, caveat, or question.
Hatziagorou et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: